# China NMPA Drug Inspection - Qiqihar Xianhe Pharmaceutical Processing Plant, Heilongjiang Province - Uncaria rhynchophylla (processed)

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/qiqihar-xianhe-pharmaceutical-processing-plant-heilongjiang-province/a1dd0a37-1faa-4ee4-be10-5775b0edb8c0/
Source feed: China

> China NMPA drug inspection for Qiqihar Xianhe Pharmaceutical Processing Plant, Heilongjiang Province published September 21, 2018. Drug: Uncaria rhynchophylla (processed). This announcement from the Heilongjiang Provincial Food and Drug Administration, dated September 21, 2018, details findi

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from the Heilongjiang Provincial Food and Drug Administration regarding 11 batches of substandard drugs (traditional Chinese medicine decoction pieces) (Issue No. 8, 2018)
- Company Name: Qiqihar Xianhe Pharmaceutical Processing Plant, Heilongjiang Province
- Publication Date: 2018-09-21
- Drug Name: Uncaria rhynchophylla (processed)
- Inspection Finding: The product's properties were substandard, and upon verification, it was confirmed that it was not manufactured by the company indicated on the label.
- Action Taken: Relevant food and drug administration departments have taken control measures such as sealing and seizing products, requiring the sampled units to stop selling and using this batch of products. Municipal (prefecture-level) food and drug administration departments will investigate and prosecute the illegal activities according to law, transferring cases suspected of constituting crimes to the public security department, and publicly disclosing the results.
- Summary: This announcement from the Heilongjiang Provincial Food and Drug Administration, dated September 21, 2018, details findings of substandard drugs and traditional Chinese medicine decoction pieces. Several companies were cited for violations. Beijing Jialin Pharmaceutical Co., Ltd. had two batches of Atorvastatin Calcium Tablets failing identification tests. Harbin Yutai Pharmaceutical Co., Ltd.'s Atractylodes lancea and Cornus officinalis batches showed issues with appearance, identification, impurities, and signs of mold or insect infestation. Anhui Zehua Traditional Chinese Medicine Decoction Pieces Co., Ltd. was cited for substandard appearance in a Bupleurum batch, and Tibet Shenhou Pharmaceutical Co., Ltd.'s Twenty-Five Flavor Coral Pills failed inspection for an unapproved substance, 808 Scarlet. Additionally, multiple batches from Qiqihar Xianhe Traditional Chinese Medicine Decoction Pieces Processing Plant, Bozhou Gongyao Decoction Pieces Factory, and Anhui Youxin Pharmaceutical Co., Ltd. were found substandard in appearance or properties. Significantly, these products were verified as not produced by the labeled manufacturers, suggesting instances of counterfeiting or misrepresentation. In response, regulatory bodies initiated control measures, including sealing and seizing the affected products and ordering a halt to their sale and use. Provincial and local food and drug administration departments are mandated to investigate and prosecute these illegal activities in accordance with Articles 73, 74, and 75 of the Drug Administration Law of the People's Republic of China. Cases suspected of criminal activity will be transferred to public security, and all handling results must be publicly disclosed within three months. This action underscores a commitment to public health and drug quality standards.

Company: https://www.globalkeysolutions.net/companies/qiqihar-xianhe-pharmaceutical-processing-plant-heilongjiang-province/9ead9b58-78a5-4122-a56f-90a18fc65166/